401566-69-6

Basic information

• Product Name: 5,6-DICHLORONICOTINIC ACID ETHYL ESTER
• Synonyms: 5,6-DICHLORONICOTINIC ACID ETHYL ESTER;5,6-DICHLOROPYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER;ETHYL 5,6-DICHLORONICOTINATE;ETHYL 5,6-DICHLOROPYRIDINE-3-CARBOXYLATE;5,6-Dichloronicotinic acid ethyl ester ,98%;3-Pyridinecarboxylic acid, 5,6-dichloro-, ethyl ester;5,6-Dichloronicotinic Acid Ethyl Ester 5,6-Dichloropyridine-3-carboxylic Acid Ethyl Ester Ethyl 5,6-Dichloropyridine-3-carboxylate
• CAS NO: 401566-69-6
• Molecular Formula: C₈H₇Cl₂NO₂
• Molecular Weight: 220.05
• Product Categories: Chloropyridines;Halopyridines
• Mol File: 401566-69-6.mol
• Article Data: 10

Chemical Properties

• Melting Point: 46°C
• Boiling Point: 281.301ºC at 760 mmHg
• Flash Point: 123.926ºC
• Appearance: /
• Density: 1.367g/cm3
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.541
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -2.72±0.10(Predicted)
• CAS DataBase Reference: 5,6-DICHLORONICOTINIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-DICHLORONICOTINIC ACID ETHYL ESTER(401566-69-6)
• EPA Substance Registry System: 5,6-DICHLORONICOTINIC ACID ETHYL ESTER(401566-69-6)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 401566-69-6(Hazardous Substances Data)

Usage

Chemical Properties

White crystalline powder

InChI:InChI=1/C8H7Cl2NO2/c1-2-13-8(12)5-3-6(9)7(10)11-4-5/h3-4H,2H2,1H3

Upstream product

• 41667-95-2 5,6-dichloronicotinic acid 
• 144-55-8 sodium hydrogencarbonate 
• 64-17-5 ethanol 

Downstream Products

• 1186637-82-0 3-chloro-5-(hydroxymethyl)picolinonitrile 
• 54127-30-9 5,6-dichloro-3-pyridinemethanol 
• 1429182-81-9 ethyl 6-acetyl-5-chloronicotinate 
• 1186617-78-6 (S)-1-amino-3-{2-ethyl-4-[5-(5-ethyl-6-pyrrolidin-1-yl-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenoxy}-propan-2-ol 
• 1186617-67-3 2-ethyl-4-[5-(5-ethyl-6-pyrrolidin-1-yl-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-6-methyl-phenol 
• 1186618-37-0 C₂₅H₃₅N₅O₃ 
• 1186617-64-0 4-[5-(6-diethylamino-5-ethyl-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenol 
• 1186617-81-1 N-((S)-3-{2-ethyl-4-[5-(5-ethyl-6-pyrrolidin-1-yl-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-6-methylphenoxy}-2-hydroxypropyl)-2-hydroxyacetamide 
• 1186617-97-9 N-((S)-3-{4-[5-(6-diethylamino-5-ethyl-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}-2-hydroxypropyl)-2-hydroxyacetamide 

Relevant articles and documents

3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH

The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are described herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant I DH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES

The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Pyridin-3-yl derivatives as immunomodulating agents

The invention relates to pyridin-3-yl derivatives of Formula (I) wherein R1, R2, R3, R4, R5; R6 and A are as described in the description, their preparation and their use as pharmaceuticall